May 03, 2021 02:46 PM IST
The sharp surge in COVID-19 cases across has created a massive demand and consequent shortage of medical oxygen and essential drugs.
- May 03, 2021 11:06 AM IST
There is a perceptible change in the Laurus Labs' management commentary in the last 18 months that points to growth sustenance for the medium term
- Apr 29, 2021 12:03 PM IST
- Apr 29, 2021 11:24 AM IST
- Apr 19, 2021 12:23 PM IST
Biocon Executive Chairperson Kiran Mazumdar Shaw says scarcity of critical anti-COVID-19 drugs Remdesivir and Itolizumab will end in 4-6 weeks as suppliers like her own company ramp up output that fell when the pandemic was receding. She said market pricing of vaccines is a must for the much-needed acceleration in inoculation.
- Apr 18, 2021 06:26 PM IST
The CRAMs ( contract research and manufacturing services) segment is fetching rich valuations globally and back home, the segment has seen minority stake sale deals like True North-Anthem Biosciences & TPG-Sai Lifesciences.
- Apr 12, 2021 08:40 PM IST
Net Sales are expected to increase by 28.3 percent Y-o-Y (up 8 percent Q-o-Q) to Rs. 1,999.6 crore, according to Sharekhan.
- Apr 12, 2021 10:58 AM IST
"Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom (UK), for its manufacturing facility at Biocon Park in Bengaluru," Biocon said in a regulatory filing.
- Apr 12, 2021 10:25 AM IST
Multi-year opportunity awaits Indian vaccine manufacturers such as DRL, Gland Pharma, Aurobindo Pharma and Cadila Pharma
- Feb 12, 2021 11:13 AM IST
This follows the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, a Biocon statement said on Friday.
- Feb 02, 2021 09:11 PM IST
Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 385 in its research report dated January 22, 2021.
- Feb 01, 2021 06:36 PM IST
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 470 in its research report dated January 22, 2021.
- Jan 28, 2021 02:58 PM IST
ICICI Direct recommended hold rating on Biocon with a target price of Rs 450 in its research report dated January 22, 2021.
- Jan 25, 2021 02:55 PM IST
Biocon’s revenue from the biologics business in Q3FY21 was Rs 769 Crore, a 11 percent increase year-on-year and 14 percent rise quarter-on-quarter, Biocon said in a BSE filing.
- Jan 25, 2021 10:00 AM IST
CLSA has retained sell on the stock and has cut target to Rs 240 from Rs 260 per share
- Jan 22, 2021 06:56 PM IST
Expenses rose to Rs 1,642.6 crore for the December quarter, an increase of 14.52 percent, as against Rs 1,434.3 crore in the year-ago period.
- Jan 22, 2021 12:00 PM IST
- Jan 22, 2021 12:00 PM IST
- Jan 22, 2021 10:02 AM IST
The generics business reported a 3 percent dip in the third quarter at Rs 561 crore, as against Rs 576 crore in the corresponding period last year.
- Jan 18, 2021 07:58 PM IST
Net Sales are expected to increase by 15.4 percent Y-o-Y (up 15.7 percent Q-o-Q) to Rs. 2,018.1 crore, according to ICICI Direct.
- Jan 08, 2021 09:51 AM IST
The transaction is subject to customary condition precedents and approvals. Post the completion of this transaction, Biocon Ltd will hold 89.89 percent stake in Biocon Biologics on a fully diluted basis, the company said.
- Jan 07, 2021 05:05 PM IST
The current investment has put the post-money valuation of Biocon Biologics at ~$4.17 billion, said Kiran Mazumdar-Shaw, Executive Chairperson of Biocon
- Dec 29, 2020 12:20 PM IST
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 520 in its research report dated December 28, 2020.
- Dec 29, 2020 09:47 AM IST
The share touched its 52-week high Rs 487.70 and 52-week low Rs 235.80 on 23 December, 2020 and 19 March, 2020, respectively.
- Dec 28, 2020 10:19 AM IST
Biocon Biologics, and Mylan have been informed by the US health regulator of deferred action on the biologics licence application for a biosimilar to drug Avastin, used to treat various types of cancers, Biocon said.